Blin, O., Desnuelle, C., Guelton, C., Aubrespy, G., Ardissonne, J. P., Crevat, A., Pouget, J., and Serratrice, G. [Anomaly in the neurotransmitter amino acids in amyotrophic lateral sclerosis: a therapeutic application]. Rev.Neurol.(Paris) 1991;147(5):392-394. View abstract.
Blin, O., Serratrice, G., Pouget, J., Aubrespy, G., Guelton, C., and Crevat, A. [Short-term double-blind vs placebo trial of L-threonine in amyotrophic lateral sclerosis]. Presse Med. 9-30-1989;18(30):1469-1470. View abstract.
Bromberg, M. B., Fries, T. J., Forshew, D. A., and Tandan, R. Electrophysiologic endpoint measures in a multicenter ALS drug trial. J.Neurol.Sci. 2-15-2001;184(1):51-55. View abstract.
Hauser, S. L., Doolittle, T. H., Lopez-Bresnahan, M., Shahani, B., Schoenfeld, D., Shih, V. E., Growdon, J., and Lehrich, J. R. An antispasticity effect of threonine in multiple sclerosis. Arch.Neurol. 1992;49(9):923-926. View abstract.
Hsieh JTC , Wolfe DL , Connolly S , Townson AF , Curt A , Blackmer J , Sequeira K , and Aubut J. Spasticity after spinal cord injury: an evidence-based review of current interventions. Topics in Spinal Cord Injury Rehabilitation (TOP SPINAL CORD INJ REHABIL) 2007;13(1):81-97.
Parton, M., Mitsumoto, H., and Leigh, P. N. Amino acids for amyotrophic lateral sclerosis / motor neuron disease. Cochrane.Database.Syst.Rev. 2003;(4):CD003457. View abstract.
Parton, M., Mitsumoto, H., and Leigh, P. N. WITHDRAWN: Amino acids for amyotrophic lateral sclerosis / motor neuron disease. Cochrane.Database.Syst.Rev. 2008;(2):CD003457. View abstract.
Rose, W. C., HAINES, W. J., WARNER, D. T., and JOHNSON, J. E. The amino acid requirements of man. II. The role of threonine and histidine. J.Biol.Chem. 1951;188(1):49-58. View abstract.
Shakespeare, D. T., Boggild, M., and Young, C. Anti-spasticity agents for multiple sclerosis. Cochrane.Database.Syst.Rev. 2003;(4):CD001332. View abstract.
Testa, D., Caraceni, T., Fetoni, V., and Girotti, F. Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study. Clin.Neurol.Neurosurg. 1992;94(1):7-9. View abstract.
Blin O, Pouget J, Aubrespy G, et al. A double-blind placebo controlled trial of L-threonine in amyotrophic lateral sclerosis. J Neurol 1992;239:79-81. View abstract.
Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: The National Academies Press, 2005. Available at: https://doi.org/10.17226/10490
Growdon JH, Nader TM, Schoenfeld J, Wortman RJ. L-threonine in the treatment of spasticity. Clin Neuropharmacol 1991;14:403-12. View abstract.
Lee A, Patterson V. A double blind study of L-threonine in patients with spinal spasticity. Acta Neurol Scand 1993;88:334-8. View abstract.
National Research Council (US) Subcommittee on the Tenth Edition of the Recommended Dietary Allowances. Recommended Dietary Allowances: 10th Edition. Washington (DC): National Academies Press (US); 1989. 6, Protein and Amino Acids. https://www.ncbi.nlm.nih.gov/books/NBK234922/. Accessed August 7th, 2017.
Roufs JB. L-threonine as a symptomatic treatment for amyotrophic lateral sclerosis (ALS). Med Hypotheses 1991;34:20-3. View abstract.
Tandan R, Bromberg MB, Forshew D, et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology 1996;47:1220-6. View abstract.